Global Klebsiella Pneumoniae Infection Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Klebsiella Pneumoniae Infection Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Klebsiella Pneumoniae Infection Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Klebsiella Pneumoniae Infection Drug market include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and Melinta Therapeutics Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Klebsiella Pneumoniae Infection Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Klebsiella Pneumoniae Infection Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Klebsiella Pneumoniae Infection Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Klebsiella Pneumoniae Infection Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Klebsiella Pneumoniae Infection Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Klebsiella Pneumoniae Infection Drug sales, projected growth trends, production technology, application and end-user industry.
Klebsiella Pneumoniae Infection Drug Segment by Company
Acies Bio doo
Appili Therapeutics
Debiopharm International SA
Evaxion Biotech ApS
FOB Synthesis Inc
ImmunoClin Corp
Innovation Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Nosopharm SAS
Peptilogics Inc
Phico Therapeutics Ltd
Sarepta Therapeutics Inc
Shionogi & Co Ltd
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Pfizer Inc
F. Hoffmann-La Roche Ltd
Klebsiella Pneumoniae Infection Drug Segment by Type
ATI-1503
CA-824
CC-1807
Cefiderocol
Debio-1454
EBX-004
Others
Klebsiella Pneumoniae Infection Drug Segment by Application
Hospital
Clinic
Others
Klebsiella Pneumoniae Infection Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Klebsiella Pneumoniae Infection Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Klebsiella Pneumoniae Infection Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Klebsiella Pneumoniae Infection Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Klebsiella Pneumoniae Infection Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Klebsiella Pneumoniae Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Klebsiella Pneumoniae Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Klebsiella Pneumoniae Infection Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Klebsiella Pneumoniae Infection Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Klebsiella Pneumoniae Infection Drug industry.
Chapter 3: Detailed analysis of Klebsiella Pneumoniae Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Klebsiella Pneumoniae Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Klebsiella Pneumoniae Infection Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Klebsiella Pneumoniae Infection Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Klebsiella Pneumoniae Infection Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Klebsiella Pneumoniae Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Klebsiella Pneumoniae Infection Drug market include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and Melinta Therapeutics Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Klebsiella Pneumoniae Infection Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Klebsiella Pneumoniae Infection Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Klebsiella Pneumoniae Infection Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Klebsiella Pneumoniae Infection Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Klebsiella Pneumoniae Infection Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Klebsiella Pneumoniae Infection Drug sales, projected growth trends, production technology, application and end-user industry.
Klebsiella Pneumoniae Infection Drug Segment by Company
Acies Bio doo
Appili Therapeutics
Debiopharm International SA
Evaxion Biotech ApS
FOB Synthesis Inc
ImmunoClin Corp
Innovation Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Nosopharm SAS
Peptilogics Inc
Phico Therapeutics Ltd
Sarepta Therapeutics Inc
Shionogi & Co Ltd
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Pfizer Inc
F. Hoffmann-La Roche Ltd
Klebsiella Pneumoniae Infection Drug Segment by Type
ATI-1503
CA-824
CC-1807
Cefiderocol
Debio-1454
EBX-004
Others
Klebsiella Pneumoniae Infection Drug Segment by Application
Hospital
Clinic
Others
Klebsiella Pneumoniae Infection Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Klebsiella Pneumoniae Infection Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Klebsiella Pneumoniae Infection Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Klebsiella Pneumoniae Infection Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Klebsiella Pneumoniae Infection Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Klebsiella Pneumoniae Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Klebsiella Pneumoniae Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Klebsiella Pneumoniae Infection Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Klebsiella Pneumoniae Infection Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Klebsiella Pneumoniae Infection Drug industry.
Chapter 3: Detailed analysis of Klebsiella Pneumoniae Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Klebsiella Pneumoniae Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Klebsiella Pneumoniae Infection Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
207 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Klebsiella Pneumoniae Infection Drug Sales Value (2020-2031)
- 1.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume (2020-2031)
- 1.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Klebsiella Pneumoniae Infection Drug Market Dynamics
- 2.1 Klebsiella Pneumoniae Infection Drug Industry Trends
- 2.2 Klebsiella Pneumoniae Infection Drug Industry Drivers
- 2.3 Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges
- 2.4 Klebsiella Pneumoniae Infection Drug Industry Restraints
- 3 Klebsiella Pneumoniae Infection Drug Market by Company
- 3.1 Global Klebsiella Pneumoniae Infection Drug Company Revenue Ranking in 2024
- 3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Company (2020-2025)
- 3.3 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Company (2020-2025)
- 3.4 Global Klebsiella Pneumoniae Infection Drug Average Price by Company (2020-2025)
- 3.5 Global Klebsiella Pneumoniae Infection Drug Company Ranking (2023-2025)
- 3.6 Global Klebsiella Pneumoniae Infection Drug Company Manufacturing Base and Headquarters
- 3.7 Global Klebsiella Pneumoniae Infection Drug Company Product Type and Application
- 3.8 Global Klebsiella Pneumoniae Infection Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Klebsiella Pneumoniae Infection Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Klebsiella Pneumoniae Infection Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Klebsiella Pneumoniae Infection Drug Market by Type
- 4.1 Klebsiella Pneumoniae Infection Drug Type Introduction
- 4.1.1 ATI-1503
- 4.1.2 CA-824
- 4.1.3 CC-1807
- 4.1.4 Cefiderocol
- 4.1.5 Debio-1454
- 4.1.6 EBX-004
- 4.1.7 Others
- 4.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type
- 4.2.1 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Type (2020-2031)
- 4.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Type (2020-2031)
- 4.3 Global Klebsiella Pneumoniae Infection Drug Sales Value by Type
- 4.3.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Type (2020-2031)
- 4.3.3 Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Type (2020-2031)
- 5 Klebsiella Pneumoniae Infection Drug Market by Application
- 5.1 Klebsiella Pneumoniae Infection Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application
- 5.2.1 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Volume by Application (2020-2031)
- 5.2.3 Global Klebsiella Pneumoniae Infection Drug Sales Volume Share by Application (2020-2031)
- 5.3 Global Klebsiella Pneumoniae Infection Drug Sales Value by Application
- 5.3.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Application (2020-2031)
- 5.3.3 Global Klebsiella Pneumoniae Infection Drug Sales Value Share by Application (2020-2031)
- 6 Klebsiella Pneumoniae Infection Drug Regional Sales and Value Analysis
- 6.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2020-2031)
- 6.2.1 Global Klebsiella Pneumoniae Infection Drug Sales by Region: 2020-2025
- 6.2.2 Global Klebsiella Pneumoniae Infection Drug Sales by Region (2026-2031)
- 6.3 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region (2020-2031)
- 6.4.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region: 2020-2025
- 6.4.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Region (2026-2031)
- 6.5 Global Klebsiella Pneumoniae Infection Drug Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Klebsiella Pneumoniae Infection Drug Sales Value (2020-2031)
- 6.6.2 North America Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Klebsiella Pneumoniae Infection Drug Sales Value (2020-2031)
- 6.7.2 Europe Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Klebsiella Pneumoniae Infection Drug Sales Value (2020-2031)
- 6.9.2 South America Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Klebsiella Pneumoniae Infection Drug Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Klebsiella Pneumoniae Infection Drug Sales Value Share by Country, 2024 VS 2031
- 7 Klebsiella Pneumoniae Infection Drug Country-level Sales and Value Analysis
- 7.1 Global Klebsiella Pneumoniae Infection Drug Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Klebsiella Pneumoniae Infection Drug Sales by Country (2020-2031)
- 7.3.1 Global Klebsiella Pneumoniae Infection Drug Sales by Country (2020-2025)
- 7.3.2 Global Klebsiella Pneumoniae Infection Drug Sales by Country (2026-2031)
- 7.4 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2020-2031)
- 7.4.1 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2020-2025)
- 7.4.2 Global Klebsiella Pneumoniae Infection Drug Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 France Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 China Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 India Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Klebsiella Pneumoniae Infection Drug Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Klebsiella Pneumoniae Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Klebsiella Pneumoniae Infection Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Acies Bio doo
- 8.1.1 Acies Bio doo Comapny Information
- 8.1.2 Acies Bio doo Business Overview
- 8.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.1.5 Acies Bio doo Recent Developments
- 8.2 Appili Therapeutics
- 8.2.1 Appili Therapeutics Comapny Information
- 8.2.2 Appili Therapeutics Business Overview
- 8.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.2.5 Appili Therapeutics Recent Developments
- 8.3 Debiopharm International SA
- 8.3.1 Debiopharm International SA Comapny Information
- 8.3.2 Debiopharm International SA Business Overview
- 8.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.3.5 Debiopharm International SA Recent Developments
- 8.4 Evaxion Biotech ApS
- 8.4.1 Evaxion Biotech ApS Comapny Information
- 8.4.2 Evaxion Biotech ApS Business Overview
- 8.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.4.5 Evaxion Biotech ApS Recent Developments
- 8.5 FOB Synthesis Inc
- 8.5.1 FOB Synthesis Inc Comapny Information
- 8.5.2 FOB Synthesis Inc Business Overview
- 8.5.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.5.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.5.5 FOB Synthesis Inc Recent Developments
- 8.6 ImmunoClin Corp
- 8.6.1 ImmunoClin Corp Comapny Information
- 8.6.2 ImmunoClin Corp Business Overview
- 8.6.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.6.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.6.5 ImmunoClin Corp Recent Developments
- 8.7 Innovation Pharmaceuticals Inc
- 8.7.1 Innovation Pharmaceuticals Inc Comapny Information
- 8.7.2 Innovation Pharmaceuticals Inc Business Overview
- 8.7.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.7.5 Innovation Pharmaceuticals Inc Recent Developments
- 8.8 Kyorin Pharmaceutical Co Ltd
- 8.8.1 Kyorin Pharmaceutical Co Ltd Comapny Information
- 8.8.2 Kyorin Pharmaceutical Co Ltd Business Overview
- 8.8.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.8.5 Kyorin Pharmaceutical Co Ltd Recent Developments
- 8.9 Melinta Therapeutics Inc
- 8.9.1 Melinta Therapeutics Inc Comapny Information
- 8.9.2 Melinta Therapeutics Inc Business Overview
- 8.9.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.9.5 Melinta Therapeutics Inc Recent Developments
- 8.10 Nosopharm SAS
- 8.10.1 Nosopharm SAS Comapny Information
- 8.10.2 Nosopharm SAS Business Overview
- 8.10.3 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.10.5 Nosopharm SAS Recent Developments
- 8.11 Peptilogics Inc
- 8.11.1 Peptilogics Inc Comapny Information
- 8.11.2 Peptilogics Inc Business Overview
- 8.11.3 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.11.5 Peptilogics Inc Recent Developments
- 8.12 Phico Therapeutics Ltd
- 8.12.1 Phico Therapeutics Ltd Comapny Information
- 8.12.2 Phico Therapeutics Ltd Business Overview
- 8.12.3 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.12.5 Phico Therapeutics Ltd Recent Developments
- 8.13 Sarepta Therapeutics Inc
- 8.13.1 Sarepta Therapeutics Inc Comapny Information
- 8.13.2 Sarepta Therapeutics Inc Business Overview
- 8.13.3 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.13.5 Sarepta Therapeutics Inc Recent Developments
- 8.14 Shionogi & Co Ltd
- 8.14.1 Shionogi & Co Ltd Comapny Information
- 8.14.2 Shionogi & Co Ltd Business Overview
- 8.14.3 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.14.5 Shionogi & Co Ltd Recent Developments
- 8.15 Syntiron LLC
- 8.15.1 Syntiron LLC Comapny Information
- 8.15.2 Syntiron LLC Business Overview
- 8.15.3 Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.15.5 Syntiron LLC Recent Developments
- 8.16 Tetraphase Pharmaceuticals Inc
- 8.16.1 Tetraphase Pharmaceuticals Inc Comapny Information
- 8.16.2 Tetraphase Pharmaceuticals Inc Business Overview
- 8.16.3 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.16.5 Tetraphase Pharmaceuticals Inc Recent Developments
- 8.17 Pfizer Inc
- 8.17.1 Pfizer Inc Comapny Information
- 8.17.2 Pfizer Inc Business Overview
- 8.17.3 Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.17.5 Pfizer Inc Recent Developments
- 8.18 F. Hoffmann-La Roche Ltd
- 8.18.1 F. Hoffmann-La Roche Ltd Comapny Information
- 8.18.2 F. Hoffmann-La Roche Ltd Business Overview
- 8.18.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.18.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
- 8.18.5 F. Hoffmann-La Roche Ltd Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Klebsiella Pneumoniae Infection Drug Value Chain Analysis
- 9.1.1 Klebsiella Pneumoniae Infection Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Klebsiella Pneumoniae Infection Drug Sales Mode & Process
- 9.2 Klebsiella Pneumoniae Infection Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Klebsiella Pneumoniae Infection Drug Distributors
- 9.2.3 Klebsiella Pneumoniae Infection Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
